ARTICLE

EFFICIENCY ASSESSMENT AND STRATEGIC INSIGHTS FOR ENHANCING PHARMACEUTICAL INDUSTRY PERFORMANCE IN PAKISTAN A DATA ENVELOPMENT ANALYSIS APPROACH

  1. HOME
  2. ARTICLE

12 Pages : 78-91

http://dx.doi.org/10.31703/gpsr.2023(VIII-I).12      10.31703/gpsr.2023(VIII-I).12      Published : Mar 2023

Efficiency Assessment and Strategic Insights for Enhancing Pharmaceutical Industry Performance in Pakistan: A Data Envelopment Analysis Approach

Abstract

    Pakistan's pharmaceutical sector, pivotal for GDP, employment, and poverty reduction, comprises 759 companies in dynamic growth. We employ Data Envelopment Analysis (DEA) to identify efficient firms in 2017-2018, showcasing DEA's superiority. Evaluating ten industry leaders, e.g., Merk, Abbott, and GSK, we assess variables like Assets, Liabilities, Sales, EPS, DPS, and ROE. High Noon excels in consistent efficiency, while others improved from 2017 inefficiencies. Sanofi, despite revenue, underutilized EPS, DPS, and ROE. The study emphasizes companies' global and national standings, offering revenue and resource optimization insights, and enhancing industry efficiency. Implementing suggestions aids firms and Pakistan's GDP, advancing the pharmaceutical sector. Valuable for international stakeholders to invest in Pakistan's pharmaceutical progress.

    Pharmaceutical Companies, DEA Methodology, Total Assets, Liabilities, Equity, Salaries, Wages, and other benefits, Sales, Earning Per Share (EPS)

    (1) Muhammad Gulraiz Tariq
    PhD Scholar, Department of Business Administration, Ghazi University, Dera Ghazi Khan, Punjab, Pakistan.
    (2) Muhammad Ziaullah
    Associate Professor, Department of Business Administration, Ghazi University, Dera Ghazi Khan, Punjab, Pakistan.
    (3) Asghar Hayyat
    PhD Scholar, Department of Business Administration, Ghazi University, Dera Ghazi Khan, Punjab, Pakistan.
    (4) Aatzaz Hassan
    Assistant Education Officer, School Education Department, District School Education Authority, Dera Ghazi Khan, Punjab, Pakistan.
    (5) Muhammad Yousif
    Ph.D. Scholar, Department of Business Administration, Ghazi University, Dera Ghazi Khan, Punjab, Pakistan.
Fulltext PDF

References

  • Acemoglu, D., & Johnson, S. (2007). Disease and Development: The Effect of Life Expectancy on Economic Growth. Journal of Political Economy, 115(6), 925–985. https://doi.org/10.1086/529000
  • Akhtar, G. J. I. J. o. H., and Science, S. (2013). Indian pharmaceutical industry: an overview [B].
  • Barro, R. J. J. A. o. e., and finance. (2013). Health and economic growth [J]. Annals of Economics and Finance, 14(2): 329-366.
  • Blake, H. (2013). A history of… Eli Lilly and Co. https://pharmaphorum.com/views-and-analysis/a-history-of-eli-lilly-co
  • Blanc, L. (2015). The European Pharmaceutical Industry in a Global Economy: what drives EU exports of pharmaceuticals? [B] (Vol. 31): College of Europe Bruges, Belgium.
  • Bloom, D. E., Canning, D., & Sevilla, J. (2004). The Effect of Health on Economic Growth: A Production Function Approach. World Development, 32(1), 1–13. https://doi.org/10.1016/j.worlddev.2003.07.002
  • Board, P. S. A. S. (1992). Definition and recognition of the elements of financial statements: Australian Accounting Research Foundation [B]
  • Cosmina Lelia Voinea, & Van, H. L. (2017). Non- market strategic management. London Routledge
  • Cung, N. H. J. A. i. S. S. R. J. (2020). Determinants of Tax Burden in Vietnam [J]. World Economic, 7(6), 12-28
  • DANZON, P. M. (1997). Price Discrimination for Pharmaceuticals: Welfare Effects in the US and the EU. International Journal of the Economics of Business, 4(3), 301–322. https://doi.org/10.1080/758523212
  • Danzon, P. M., & Chao, L.-W. (2000). Cross-national price differences for pharmaceuticals: how large, and why? Journal of Health Economics, 19(2), 159–195. https://doi.org/10.1016/s0167-6296(99)00039-9
  • Danzon, P. M., Mulcahy, A. W., & Towse, A. K. (2013). Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement. Health Economics, 24(2), 238– 252. https://doi.org/10.1002/hec.3013
  • Díaz, R. F., and Sanchez-Robles, B. J. M. (2020). Non-Parametric Analysis of Efficiency: An Application to the Pharmaceutical Industry [J].Quantitative Methods of Economics and Finance, 8(9), 1522-1549
  • Duxbury, P., and Tuck, E. J. N. M. I. P. (2008). Pharmaceutical patents need a new lease of life [B]. 42
  • Haq, S. (2014). Industry woes: Drug shortage feared as consignments stuck at ports. https://tribune.com.pk/story/769399/industry-woes-drug-shortage-feared-as-consignments-stuck-at-ports
  • Hayat, D. K. (2012). Merck Pharmaceuticals (Private) Limited [OL]. https://medimoon.com/2012/09/merck-pharmaceuticals-private-limited
  • Hess, A. M., & Rothaermel, F. T. (2011). When are assets complementary? star scientists, strategic alliances, and innovation in the pharmaceutical industry. Strategic Management Journal, 32(8), 895–909. https://doi.org/10.1002/smj.916
  • Hickson, K. J. R. o. I., and Wealth. (2014). The GDP Value of Twentieth-Century Health Improvements in Developed Economies: Initial Estimates for England [B]. 60(2): 385- 399.
  • Junaidi, I. (2015). No law to stop pharma companies from importing raw materials [OL]. Retrieved from https://www.dawn.com/news/1195030
  • Bharathi Kamath, G. (2008). Intellectual capital and corporate performance in Indian pharmaceutical industry. Journal of Intellectual Capital, 9(4), 684–704. https://doi.org/10.1108/14691930810913221
  • Khan, N. (2016). Pharmaceutical industry of Pakistan. https://www.slideshare.net/NaushiiKhan/pharmaceutical-industry-of-pakistan
  • Kirim, A. S. (1985). Reconsidering patents and economic development: A case study of the Turkish pharmaceutical industry. World Development, 13(2), 219–236. https://doi.org/10.1016/0305-750x(85)90006-3
  • Kumah, A. J. I. J. o. C. I. R. (2017). Minimum wage compliance in developing countries among the informal sector workers in Ghana [B]. 3(04),
  • Langley, P. C. (1996). The November 1995 Revised Australian Guidelines for the Economic Evaluation of Pharmaceuticals. PharmacoEconomics, 9(4), 341–352. https://doi.org/10.2165/00019053-199609040-00007
  • Lee, J.-Y., & Hunt, P. (2012). Human Rights Responsibilities of Pharmaceutical Companies in Relation to Access to Medicines. The Journal of Law, Medicine & Ethics, 40(2), 220–233. https://doi.org/10.1111/j.1748-720x.2012.00660.x
  • Leeflang, R. L. I., Klein-Hesselink, D. J., & Spruit, I. P. (1992). Health effects of unemployment—I. Long-term unemployed men in a rural and an urban setting. Social Science & Medicine, 34(4), 341–350. https://doi.org/10.1016/0277-9536(92)90294-z
  • Greve, J. (2008). Healthcare in developing countries and the role of business: a global governance framework to enhance the accountability of pharmaceutical companies. Corporate Governance: The International Journal of Business in Society, 8(4), 490–505. https://doi.org/10.1108/14720700810899220
  • Madrid, Y., Velásquez, G., and Fefer, E. J. R. P. d. S. P. (1998). The economics of pharmaceuticals and health sector reform in the Americas [B]. 3, 343-350.
  • Majumdar, S., & Asgari, B. (2017). Performance Analysis of Listed Companies in the UAE-Using DEA Malmquist Index Approach. American Journal of Operations Research, 07(02), 133– 151. https://doi.org/10.4236/ajor.2017.72010
  • Mubarik, S., Chandran, V., & Devadason, E. S. (2016). Relational capital quality and client loyalty: firm-level evidence from pharmaceuticals, Pakistan. The Learning Organization, 23(1), 43–60. https://doi.org/10.1108/tlo-05-2015-0030
  • MURATOÄžLU, G. J. J. o. Y. U. (2017). Does pharmaceutical industry boost economic growth? A Competitiveness-related approach [J]. Journal of Economic Development, 12(48), 296- 314
  • MURATOÄžLU, G., MURATOÄžLU, Y. J. J. o. E., and Economy, P. (2016). Determinants of export competitiveness: evidence from OECD manufacturing [J]. Journal of Economics and Political Economy, 3(1), 111-118.
  • Nath, S. D., Islam, S., & Saha, A. K. (2015). Corporate Board Structure and Firm Performance: The Context of Pharmaceutical Industry in Bangladesh. International Journal of Economics and Finance, 7(7). https://doi.org/10.5539/ijef.v7n7p106
  • Ofoegbu, G. N., and Onodugo, V. A. (2016). Liquidity management and profit performance of pharmaceutical manufacturing firms listed in Nigeria Stock Exchange. [J] International Journal of Management Sciences and Business Research, 28(7): 141-162.Pakistan's PharmaceuticalIndustr https://primeinstitute.org/author/mohsin/
  • Mardani, A., Zavadskas, E. K., Streimikiene, D., Jusoh, A., & Khoshnoudi, M. (2017). A comprehensive review of data envelopment analysis (DEA) approach in energy efficiency. Renewable and Sustainable Energy Reviews, 70, 1298–1322. https://doi.org/10.1016/j.rser.2016.12.030
  • Shewell, P., & Migiro, S. (2016). Data envelopment analysis in performance measurement: a critical analysis of the literature. Problems and Perspectives in Management, 14(3), 705–713. https://doi.org/10.21511/ppm.14(3-3).2016.14
  • Shin, K., Lee, D., Shin, K., & Kim, E. (2018). Measuring the Efficiency of U.S. Pharmaceutical Companies Based on Open Innovation Types. Journal of Open Innovation: Technology, Market, and Complexity, 4(3), 34. https://doi.org/10.3390/joitmc4030034
  • Urias, E. (2017). The contribution of the Pharmaceutical Industry to the health status of the developing world. International Business and Management, 41–67. https://doi.org/10.1108/s1876-066x20170000033003
  • Graf von der Schulenburg, J.-M., & Hoffmann, C. (2000). Review of European guidelines for economic evaluation of medical technologies and pharmaceuticals. HEPAC Health Economics in Prevention and Care, 1(1), 2–8. https://doi.org/10.1007/s101980050002
  • Weinstei n, M. C., Siegel, J. E., Gold, M. R., Kamlet, M. S., & Russell, L. B. J. J. (1996). Recommendations of the Panel on Cost- effectiveness in Health and Medicine [J]. JAMA, 276(15), 1253-1258.
  • Yesyurun, P. J. E. J. o. M. (2021). The Determinants Factor of Dividend Payout Ratio: an Empirical Study of Bank Buku IV in Indonesia . Journal of Management Sciences, 11(2),218-224. https://doi.org/10.35335/enrichment.v11i2.71

Cite this article

APA

    APA : Tariq, M. G., Ziaullah, M., & Hayyat, A. (2023). Efficiency Assessment and Strategic Insights for Enhancing Pharmaceutical Industry Performance in Pakistan: A Data Envelopment Analysis Approach. Global Pharmaceutical Sciences Review, VIII(I), 78-91. https://doi.org/10.31703/gpsr.2023(VIII-I).12

CHICAGO

    CHICAGO : Tariq, Muhammad Gulraiz, Muhammad Ziaullah, and Asghar Hayyat. 2023. "Efficiency Assessment and Strategic Insights for Enhancing Pharmaceutical Industry Performance in Pakistan: A Data Envelopment Analysis Approach." Global Pharmaceutical Sciences Review, VIII (I): 78-91 doi: 10.31703/gpsr.2023(VIII-I).12

HARVARD

    HARVARD : TARIQ, M. G., ZIAULLAH, M. & HAYYAT, A. 2023. Efficiency Assessment and Strategic Insights for Enhancing Pharmaceutical Industry Performance in Pakistan: A Data Envelopment Analysis Approach. Global Pharmaceutical Sciences Review, VIII, 78-91.

MHRA

    MHRA : Tariq, Muhammad Gulraiz, Muhammad Ziaullah, and Asghar Hayyat. 2023. "Efficiency Assessment and Strategic Insights for Enhancing Pharmaceutical Industry Performance in Pakistan: A Data Envelopment Analysis Approach." Global Pharmaceutical Sciences Review, VIII: 78-91

MLA

    MLA : Tariq, Muhammad Gulraiz, Muhammad Ziaullah, and Asghar Hayyat. "Efficiency Assessment and Strategic Insights for Enhancing Pharmaceutical Industry Performance in Pakistan: A Data Envelopment Analysis Approach." Global Pharmaceutical Sciences Review, VIII.I (2023): 78-91 Print.

OXFORD

    OXFORD : Tariq, Muhammad Gulraiz, Ziaullah, Muhammad, and Hayyat, Asghar (2023), "Efficiency Assessment and Strategic Insights for Enhancing Pharmaceutical Industry Performance in Pakistan: A Data Envelopment Analysis Approach", Global Pharmaceutical Sciences Review, VIII (I), 78-91

TURABIAN

    TURABIAN : Tariq, Muhammad Gulraiz, Muhammad Ziaullah, and Asghar Hayyat. "Efficiency Assessment and Strategic Insights for Enhancing Pharmaceutical Industry Performance in Pakistan: A Data Envelopment Analysis Approach." Global Pharmaceutical Sciences Review VIII, no. I (2023): 78-91. https://doi.org/10.31703/gpsr.2023(VIII-I).12